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Alzheimer’s treatments. We describe alternative approaches on how to leverage specialist time for memory care in this narrative synthesis based on 17 semi-structured interviews and a targeted literature review
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the local context.
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Disease-modifying treatments for Alzheimer’s disease (AD) may become available soon; the leading candidate,
aducanumab, is awaiting US FDA approval in June 2021 [1], with other promising candidates, gantenerumab,
BAN2401 and ALZ-801, following close behind in several ongoing Phase III clinical trials [2,3]. In contrast to the
current treatment paradigm, where treatments for symptom management are started after progression to the later
stages of dementia, the secondary prevention paradigm of these disease-modifying treatments would necessitate
diagnosis of AD during the mild cognitive impairment or early dementia stages so that treatment can be started
early enough to delay the progression to late-stage disease.
Although prevalence estimates for mild cognitive impairment depend on the criteria used [4], Petersen et al.
estimates that the prevalence of mild cognitive impairment is as high as 15–20% in people 60 years or older
based on a review of many international population-based studies [5]. Being an earlier disease stage, mild cognitive
impairment has milder symptomatology and clinical findings than dementia, and is therefore, more difficult to
diagnosis, and until now, there has not been an urgent need to evaluate patients with subtle memory complaints for
mild cognitive impairment. A sudden spike in demand to evaluate the large reservoir of prevalent cases of early-stage
AD during the initial years after disease-modifying treatments become available, may therefore, pose a significant
challenge to healthcare systems. As the COVID pandemic has shown, even well-resourced health systems struggle
to adapt to such sudden spikes, implying the need to pre-emptively identify and address gaps in our healthcare
infrastructure.
As noted by the Alzheimer’s Association 2020 report, there is currently a shortage of dementia specialists,
including geriatricians, neurologists, geriatric psychiatrists and neuropsychologists, in the USA [6]. Previous research
demonstrated that the increase in demand for evaluation and disease-modifying treatment would likely overwhelm
specialist capacity [7]. The study used a simulation model to estimate that approximately 88 million individuals in
the USA may need to be assessed for the presence of mild cognitive impairment, and almost 15 million individuals
with suspected mild cognitive impairment may need specialist referral for further evaluation. However, the specialist
workforce can only accommodate an estimated 1.9–6.3 million additional visits per year on top of their current
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workload. This discrepancy between supply and demand was projected to result in wait times of over 12-months
lasting for several years and could potentially lead to two million US patients progressing to late stage dementia
while on the wait list. Other countries, including Canada, France, Germany, Italy, Spain, Sweden, Australia and
Japan, are estimated to face similar capacity constraints [8–11]. Follow-on work in the USA and the five largest EU
countries also suggested that existing models of memory care are ill-equipped to handle the medicalized nature of
a disease-modifying treatment, because today’s practices are limited in scale and scope and focus on documenting
degree and patterns of cognitive decline as well as referrals to social services [12,13].
Against this background, the aim of this article is to describe approaches to memory care in the USA and other
countries that leverage specialist time more effectively with the use of task shifting to primary care physicians
and other clinical and nonclinical staff. Wells et al. had previously conducted a review of innovative diagnostic
care pathways for dementia, focusing specifically on primary care clinics in England [14]. In their report, they
highlighted several approaches, from primary-care led clinics where the general practitioner was supported by either
a multidisciplinary team, specialist consultant access and/or specialized nursing support; monthly memory clinics
that are embedded within a primary care clinic; to secondary-led clinics following primary care referral. Their
findings suggested that greater primary care involvement in dementia diagnosis was beneficial to patient satisfaction
and with potential improvement to referral and diagnostic times. Dreier-Wolfgramm et al. similarly reviewed
collaborative primary care models for dementia, summarizing six examples from four countries (Germany, US,
UK and The Netherlands) to highlight how different stakeholders from general practitioners, dementia specialists,
nurses, pharmacists, case managers to social workers, can come together in the primary care setting either as a
dementia team or network to improve patient care [15].
We are building on this work in two ways. First, we are including other approaches besides primary care models
to leverage scarce specialists, namely tools and technology, and reorganization of specialty practices. Second, we
propose a typology of approaches.
After describing the methodology behind this narrative synthesis, we start by presenting the guideline-concordant
and the real-life diagnostic process and the roles of the primary care physicians and specialists in the journey of
patients with mild cognitive impairment or early dementia. We describe the alternative approaches to alleviating
specialist capacity constraints, focusing on the USA, but also drawing from experiences in other countries. There
are no examples specifically for mild cognitive impairment and early-stage dementia, and so the existing examples
discussed in this report mainly target later stage dementia patients. However, these dementia care models may be
expanded to include care for mild cognitive impairment and early-stage dementia patients. The paper ends with a
discussion of the limitations and future directions.
Materials & methods
This narrative synthesis is based on a total of 17, 1/2–1 h, semi-structured interviews with primary care physicians,
neurologists, geriatricians and geriatric psychiatrists practicing in the USA and Canada. The interviewees were
identified through convenience sampling of healthcare practitioners, who had published peer-reviewed articles
on AD or dementia diagnosis and/or care models, were listed with their contact information as a clinical staff
member in relevant departments within major healthcare systems or were listed as an investigator on the Geriatrics
Workforce Enhancement Program grant website [16]. The list of questions for the interviews are presented in the
Appendix (Supplementary data). Briefly, we asked the physicians to walk us through the typical diagnostic pathway
for a patient presenting with a subjective memory complaint with a focus on the respective roles of primary and
specialty care. We invited them to share their insights into actual or hypothetical care models that would leverage
scarce specialist time by shifting tasks to primary care physicians and other providers as well as into technologies
that would facilitate such task shifting. As the study did not constitute human subjects research per US federal
regulations (45 CFR 46, 102[f ]) [17], it was exempt from internal review board (IRB) review and registration.
We performed a thematic analysis to identify broad categories of approaches to memory care. We searched the
published literature, as well as websites of government agencies, professional organizations and large academic and/or
medical centers, for real-world examples of these alternative care approaches to illustrate how these approached
have been applied and, if results were available and published, how they have fared.
Results
Guideline-concordant evaluation of cognitive decline

In the absence of sufficient evidence for net clinical benefit, systematic screening for mild cognitive impairment is
currently not recommended or covered in the USA and other countries [17–21]. Outside of the Medicare Annual
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Subjective cognitive and/or memory
concerns by patients and/or informant

Initial H&P
• Brief cognitive testing
• Rule out of common and/or
reversible causes of cognitive
impairment, such as depression
and substance use
• Document course of cognitive
impairment
• Review of medications

PiB-PET imaging (or CSF AE testing)

Laboratory testing
e.g., vitamin B12,
thyroid function

Special Report

Neuroimaging
for focal brain
processes

In-depth evaluation
• Neurocognitive testing to
determine degree and
pattern of cognitive
impairment
• Neurological exam

Figure 1. Diagnostic pathway of patients with memory complaints and possible Alzheimer’s disease.
CSF Aβ: Cerebral spinal fluid amyloid-beta; H&P: History & Physical; Pib-PET: Pittsburg compound B-positron emission
tomography.

Wellness Visit, which is mandated to include a cognitive assessment, patients are usually only evaluated for cognitive
impairment when they present with subjective memory complaints.
Because subjective memory complaints are insufficient to establish a diagnosis of cognitive impairment, physicians
should evaluate the patient with a validated instrument to verify the presence of cognitive impairment and to
characterize its degree and pattern [22]. Several brief cognitive tests, including the General Practitioner Assessment
of Cognition and the mini-Assessment of Cognition [23,24], are adequate for detecting possible dementia. However,
mild cognitive impairment, or even mild dementia, is more difficult to detect than dementia because the impairment
at these earlier stages is subtler. Although still limited in their diagnostic accuracies for mild cognitive impairment, the
best-established tests are the Mini-Mental Status Exam (MMSE) and the Montreal Cognitive Assessment [18,25,26].
Comprehensive neuropsychological testing should follow for patients, who test positive in order to confirm the
presence of cognitive decline and determine the exact stage of decline, because a disease-modifying treatment would
only be indicated in early stages of the disease.
The initial evaluation (Figure 1) [19] would also include a medical history, physical exam and diagnostic tests to
identify or rule out other possible causes, including but not limited to cerebrovascular disease, thyroid dysfunction,
electrolyte abnormalities, vitamin deficiencies, infectious diseases, liver disease, depression, medications or drug use.
Structural imaging with computed tomography (CT) or MRI may be done to rule out focal neurological processes.
If AD is the suspected etiology of the cognitive impairment, cerebrospinal fluid testing or positron emission
tomography scan for amyloid-beta may be conducted to confirm or rule out the diagnosis. While cerebrospinal
fluid amyloid-beta testing has been approved in Europe, only amyloid positron emission tomography has received
FDA approval and neither test is currently covered outside of clinical trials or registries [27].

Evaluation of memory complaints under real-world conditions

Primary care is usually the initial point of contact for patients with memory concerns. We were told in our
interviews with primary care physicians and specialists that there is a wide variation in how primary care physicians
manage patients with suspected cognitive impairment in current real-world practice. While a few follow guideline
recommendations, most do not inquire proactively about cognitive decline or even discount subjective memory
complaints as normal aging, which may result in missed or delayed diagnosis of dementia [28,29].
Formal assessment with a validated brief cognitive test is even less common, as even the simple General Practitioner
Assessment of Cognition and the mini-Assessment of Cognition [30] take approximately 5 min to administer and
score, and the more precise MMSE or Montreal Cognitive Assessment around 15 min. Laboratory testing for
potentially reversible causes of cognitive impairment is inconsistently done and neuroimaging is rarely ordered
in primary care settings. The most typical approach is to refer the patient to a specialist without any further
evaluation, placing the entire diagnostic process into the hand of specialists. Commonly voiced reasons for the
reluctance of primary care physicians to assume a greater role in evaluating cognitive complaints include time
constraints, workflow considerations and insufficient tools, knowledge and skills.
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Alternative care approaches

From our interviews, we identified several alternatives care approaches that may enable nonspecialist clinicians
to assume a greater role in the initial diagnostic workup of patients with suspected cognitive impairment, with
strategic use of specialist resources. The alternative approaches can be broadly classified into four categories based
on the care setting:





Community primary care practices;
Primary care memory clinics;
Specialty memory clinics;
Specialty centers.

Developing competencies in community primary care practices

There is an ongoing concern in countries as varied as Germany, Hungary, Singapore, Saudi Arabia, Nepal, the USA
and the UK that primary care training in geriatric medicine and dementia care may not be robust enough [31–37]. A
survey of general internal medicine residency programs in the USA reported that 93% of programs had a required
geriatrics curriculum, but 71% of the programs only required 13–36 half days of geriatric training during the 3-year
residency, with the remaining 29% requiring only 12 half days or less of geriatric training [38].
Two potential solutions to overcome the lack of training would be the introduction of tools and technologies
to simplify the decision process and improve capabilities. As an example for tools, Kaiser Permanente published
an informational dementia guideline through their Care Management Institute, consolidating evidence-based
recommendations about every step in the care pathway from screening to treatment [19]. The guideline not only
summarizes the important components of the patient history and physical exam, but also, specifically recommends
the MMSE for cognitive assessment, lists out the diagnostic tests that should be ordered as part of the routine
work-up and details when and what type of neuroimaging should be ordered and when the patient should be
referred to a specialist. Blood-based biomarkers [39,40] and computerized cognitive testing [41–43] are examples of
technologies that are currently being developed to further simplify the initial diagnostic process.
Education programs, such as the Evidence-based Interventions in Dementia project in the UK or the Connecticut
Older Adult Collaborative for Health (COACH) program in the USA, may further help improve primary care
physicians’ ability to manage a greater part of the evaluation process. The EVIDEM-ED project developed
customized practice-based workshops for general practitioners with the aim to improve clinical recognition and
management of dementia [44]. The COACH program on the other hand aims to improve the health of the
elderly through a multiorganizational, multidisciplinary geriatric education center [45]. COACH is a collaborative
network of experts, primary care physicians and other health professionals to disseminate knowledge and expertise
and promote best practices in the community. COACH is just one example of the educational programs targeting
geriatric care that are funded by the Health Resources and Services Administration through its Geriatrics Workforce
Enhancement Program [16].
Educational programs can utilize existing telehealth technology to develop telementoring programs like
Project Extension for Community Healthcare Outcomes (ECHO) [46,47]. Developed by the University of New
Mexico (UNM) Health Sciences Center, Project ECHO is a remote learning program to address obstacles to access
to specialty care in rural areas. Realizing that many patients with chronic conditions live in rural areas that are
too far from major health systems to receive specialty care, specialists at UNM partnered with rural primary care
physicians to form ‘a community of practice’ [48]. In addition to providing care protocols for rural primary care
physicians, UNM specialists and the rural primary care physicians meet weekly via videoconference for teleECHO
lectures and grand rounds to review and discuss cases. Project ECHO was initially developed for the management
of hepatitis C, but the model has been since replicated by other centers [49] for a myriad of other conditions, such
as osteoporosis [47], chronic pain [48], rheumatology [50], diabetes [51], geriatrics [52] and end-of-life care for patients
with advanced dementia [53].
More recently, the Alzheimer’s Association launched a 6-month pilot Project ECHO program to train primary
care physicians in community-based dementia care [54]. The program brings together expert multidisciplinary
specialist teams and primary care practices in bi-weekly interactive learning sessions. Based on the Alzheimer’s
Association’s Dementia Care Guidance for HealthCare Professionals, the learning sessions consists of instructional
presentations and case-based discussions. Primary care physicians are provided with guidance on which patients
to evaluate, validated tools for cognitive assessment, indications for referral, diagnostic criteria for AD and mild
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cognitive impairment and medical management. There is also a companion pilot that connects nonphysician
participants from assisted-living facilities with dementia care experts [55].
The effectiveness of educational interventions has been mixed. A unblinded cluster-randomized controlled trial
evaluating the impact of the Evidence-based Interventions in Dementia practice-based workshops found that the
educational intervention did not increase dementia detection rates [56]. On the other hand, another study comparing
an electronic tutorial, a decision support software and practice-based workshops found that all three educational
interventions improved the detection rate for dementia compared with the control group. Dementia detection rate
was 11% in the control arm, 20% in the electronic tutorial arm, 30% in the decision support software arm and
31% in the practice-based workshop arm [57].
A systematic literature review of the impact of Project ECHO models on provider and patient-related outcomes
by McBain et al. [58] found favorable evidence of provider satisfaction, increased knowledge and increased clinical
confidence. Some evidence suggested improved patient-related outcomes, including improved access for patients,
reduced healthcare resource utilization and better clinical outcomes. However, McBain et al. found that the evidence
was generally low-quality, retrospective, nonexperimental and, thus, subject to bias.
Primary care memory clinics

A further evolution of the role of primary care physicians is the emergence of primary care memory clinics. Primary
care collaborative memory clinics (PCCMC) originated in ON in 2006 to address specialist capacity constraints in
dementia care [59]. PCCMCs are multidisciplinary teams that include one or two primary care physicians, two to
three nurses, a social worker and administrative support staff. Depending on resource availability, some PCCMCs
also include a pharmacist, an occupational therapist and even representatives from the local AD association to
provide additional information, education and support to patients and their caregivers. While PCCMCs are led
by specially trained primary care physicians in its routine operations, designated specialists are available to each
memory clinic for consultation via telephone or e-mail. Referral to specialists is reserved for complex cases.
The physicians leading each PCCMC are usually full-time primary care physicians with their own general practice,
but they devote 1–2 days a month to the memory clinic, assessing patients referred to them by their primary care
colleagues [60]. The physicians had to complete an accredited, 5-day Memory Clinic Training Program to develop
real-world competencies on how to operate a memory clinic and skills related to the assessment and management
of patients with memory problems. The training program consists of a 2-day workshop, a day of observation and
training at the Center for Family Medicine Memory Clinic and finally 2 days of on-site mentorship at the newly
formed memory clinic. Learning is facilitated through case-based discussions, problem-solving exercises, pocket cue
cards and coaching. Booster sessions are also scheduled to allow previously trained teams to update their learning
and share best practices.
PCCMCs work collaboratively with the patient’s own primary care physicians to coordinate care, ensuring that
care for most patients remains in the hands of their established primary care physician. While referral rates to
specialists for memory concerns are reportedly as high as 82% in Canada under usual practice [61], PCCMCs have
referral rates of approximately 10% [59,62,63], and wait times for specialty care have as a result been shortened [64].
There are 92 PCCMCs across ON as of 2017 [65].
The Gnosall memory clinic model in the UK is another example of a primary care memory clinic model [66].
Distinct from the ON PCCMC model, it is not led by a specialized primary care physician. Instead, it embeds
a part-time eldercare facilitator and a monthly specialist-led memory clinic within the primary care clinic. The
specialist will be available by telephone and email for consultation between the monthly memory clinic dates.
In the Gnosall memory clinic pathway, the patient’s primary care physician conducts the initial evaluation. For the
patient who requires further evaluation by a specialist, an eldercare facilitator will arrange to meet with the patient
and the patient’s family member or caregiver, usually at the patient’s home, to gather additional information. The
patient is then evaluated at the monthly primary care memory clinics by the specialist with the eldercare facilitator
present. The specialists will diagnose the patient and formulate a treatment plan. The eldercare facilitator will
coordinate the care of the patient between the primary care physician and the specialists for as long as needed
and will identify and refer the patient and the patient’s family members to additional resources as appropriate. An
evaluation of the model suggests that it reduced cost compared with a specialist-led model and achieved high levels
of satisfaction among patients and their families [67].
Another primary care memory clinic model uses dementia nurses to facilitate care [68,69]. In the Norway model [69],
a local dementia team, consisting of either two nurses or a nurse and an occupational therapist, gathers clinical
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information to assist the primary care physician with the diagnosis. The dementia team is trained on cognitive
assessment procedures and can administer and help interpret the MMSE, the clock drawing test, the ‘informant
questionnaire on cognitive decline in the elderly-16 item’ version and the instrumental ‘activities of daily living’
scale. Primary care physicians receive a checklist for the physical exam and laboratory testing and guidance on
when neuroimaging should be performed. There is also a standardized case record file and a diagnostic guide for
the dementia team and the patient’s primary care physician to use. The impact of these models on patient care and
clinical outcomes remain unclear; the original papers that described the models did not report on its performance,
nor have we identified any subsequent publications.
Specialty memory clinics

Specialty clinics in neurology, geriatrics and geriatric psychiatry with a high volume of patients with memory
disorders may want to further reorganize into memory clinics [70]. In addition to specialist physicians, the core
team of specialty memory clinics might include a clinical psychologist, who can conduct in-depth cognitive testing;
specialized nursing staff, who links the different components of the service together and provides continuity of
care; a liaison to Alzheimer’s societies, who serves as a lay expert-by-experience to help guide and reassure patients
and their families; and a social worker to help provide additional linkage to community resources and services.
The memory clinic may also include, either in-house or by consultation, a clinical pharmacologist, a dietitian, an
occupational therapist and a speech therapist. Ideally, the memory clinic should be connected to other specialty
clinics, such as ophthalmology and otorhinolaryngology and translator services.
Some specialty memory clinics restrict their availability to only 1–2 days a week. In such cases, key clinic staff
may continue managing memory clinic activity and ensure accessibility to patients and their families by phone or
email throughout the other days of the week.
Some clinics will prearrange for some components of the evaluation to be completed by the referring clinician
prior to the initial visit, while others will assume responsibility for the full evaluation. Many memory clinics that
operate a website include a ‘What to Expect’ section for referred patients, describing what the initial and follow-up
visits typically entail and contact information [71–74]. These informational websites help ensure that patients present
to the clinic with the requested medical records and are prepared for the extensive evaluation process ahead.
Productivity in specialty care, as measured by wait times and wait lists, can be improved by better alignment of
demands and capacity [75]. By focusing on memory disorders, specialty clinics could theoretically reduce variation
in the patient pool and allow for better planning and strategic investments on specialized equipment and training
of staff, improving the overall efficiency and productivity of the clinic. For example, the San Jose Kaiser Permanente
memory clinic assigns a case manager to each patient to coordinate care [73]. The Napa–Solano Kaiser Permanente
memory clinic offers patients a class prior to their initial visit [74]. The class discusses with patients and their
families the difference between normal age-related cognitive changes and memory disorders. Patients and their
family members will also complete a questionnaire about the memory loss symptoms during the class.
Specialty centers

Comprehensive specialty centers like the Cleveland Clinic Lou Ruvo Center for Brain Health (LRCBH) have
integrated clinical, research and community outreach capabilities [76]. With vast in-house resources, LRCBH
functions as a ‘one stop medical home’ that integrates different components of care together. It provides patients
with expert diagnosis and treatment at its outpatient clinic, caregiver programs, neuropsychology evaluations,
neuroimaging and physical and occupational therapy. Similar to the veterans affairs system [77], LRCBH has
telemedicine capabilities to reach patients who live farther away from the center. Its high patient volume, in-house
experts and cutting-edge technology and standardized evaluation process facilitate patient recruitment, clinical trial
monitoring and basic science and translational research. The center further contributes to community wellness
by organizing free-education sessions on a variety of subjects ranging from new treatment options, the advance
directive and guardian nomination registries and general wellness [78]. LRCBH has its main site in Las Vegas, NV,
USA, two sites in Cleveland, OH, USA, and another site in Weston, FL, USA. All clinical and research programs
are aligned under a single leadership to achieve efficiency of scale [76]. Spain’s Fundació ACE, Institut Català de
Neurociènces Aplicades is another example of a comprehensive AD specialty center that provides clinical care,
cutting-edge research and educational programs [79] as are the 28 Memory and Research Centers (Centres mémoire
de ressources et de recherche) in France [12].
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The National Institute on Aging (NIA) in the USA has similarly established a network of AD research facilities
since 1978 [80]. These National Institute on Aging-funded AD research centers are embedded in major academic
centers with teaching, research and clinical capabilities [81]. For example, the University of Pennsylvania Comprehensive AD Center (CADC) can be broadly divided into an administrative team, a training team, various research
teams and an outreach team. The administrative team’s role is to coordinate activities between the University of
Pennsylvania CADC and other CADCs and AD Centers. It also provides financial oversight and oversee grants,
Institutional Review Boards, Intellectual Property and corporate alliances. The training team is tasked with the
development of multidisciplinary healthcare providers and scientists, including physicians, nurses, therapists and
basic and translational scientists. Research teams try to discover, develop and disseminate novel models in diagnosis,
treatment, patient care and health policies. The outreach, education and dissemination team assists the other teams
with publications and organizes meetings with other CADCs and other public and private entities to advance the
mission of the CADCs. While specialty centers like the CDACs and LRCBH may not necessarily be able to instantaneously increase the number of specialists to meet the high demand for specialty services, they contribute research
to advance the field; train new multidisciplinary healthcare practitioners, who then return to their communities to
further disseminate the knowledge, in best care practices; and educate the community with outreach programs and
educational sessions.
Discussion
Routine screening for mild cognitive impairment is currently not standard of care, but the advent of diseasemodifying treatments for AD might trigger substantial demand for evaluation for mild cognitive impairment,
which may likely overwhelm dementia specialist capacity [7]. As increasing the number of specialists is difficult in
the short run, this paper looks at tools and alternative care approaches to use scarce specialist time more efficiently,
which we broadly grouped into four separate categories: community primary care practices; primary care memory
clinics; specialty memory clinics; and specialty centers.
The first two approaches capitalize on the primary care workforce by providing additional resources to support
primary care clinics in memory care either as part of their routine practice, or if demand requires and resources
allow, specialized memory clinics within the primary care setting. Specialist time would of course be needed to
support these two approaches to either develop the training material, run the workshops, serve as consultants for the
general practitioners and/or to establish a memory clinic within a primary care clinic. In return for this investment
in specialist time, primary care may be able to take on some of the more straightforward workload from specialists,
such as screening out negative cases of mild cognitive impairment, provide counseling to concerned patients and
manage post-diagnosis care for patients with mild cognitive impairment.
While the interest of our paper is more geared toward addressing the emerging need to diagnose mild cognitive
impairment rather than dementia care, many of the examples in our paper are drawn from dementia care models.
As such, there is much overlap between our paper and the Wells et al. [14] and Dreier-Wolfgramm et al. [15] papers,
which had, similar to our paper, highlighted how dementia care can be better incorporated into primary care with
the innovative use of case managers, specialized nursing support, multidisciplinary teams, specialist consultants
and/or multidisciplinary professional networks dedicated specifically to promoting dementia care. Our paper
provides greater details on the different types of educational resources that may be provided to general practitioners.
Extending beyond the scope of the Wells et al. and Dreier-Wolfgramm et al. papers, the last two approaches focus
on how memory clinics can be organized and operated within the specialty clinic and specialty center settings to
streamline the workflow and gain efficiencies for specialists.
Limitations

While conceptually promising, few of the approaches have been formally evaluated. Some evidence suggests that
selected approaches may improve patient care, but the evidence is usually limited in scope (e.g., only one or two
outcomes are evaluated) and/or quality (e.g., many studies relied on self-reported perceptions of change without
validation and ascertainment of changes in outcomes or surveys with low response rates). Furthermore, because
there are no real-world examples specifically for evaluation and management of mild cognitive impairment and
early-stage dementia, the examples given in this paper are drawn from dementia care and other chronic conditions.
It is unclear how well these approaches would generalize to mild cognitive impairment and early-stage dementia.
Further evaluation is warranted to learn how the various approaches impact: access to care, for example, reduce
wait-times and/or time-to-diagnosis, shorten travel distance to care; diagnosis and/or treatment rates and accuracy
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of diagnoses by primary care providers; collaborative networks established; patient, patient caregiver and healthcare
provider satisfaction; clinical outcomes and; resource utilization, for example, specialist referral rates, hospitalization
rates.
Finally, because this report builds its narrative on semi-structure interviews, supplemented with real-world
examples, it may be limited in its generalizability by the convenience sample of interviewees. While we have
missed other approaches to memory care, we believe our paper provides a good overview of the broad categories of
approaches from the primary care and specialty care perspectives.
Conclusion
We identified four types of approaches for better leverage specialist time, ranging from building-up primary
care capabilities to operating efficient specialty centers that holistically ties in research, patient care and education.
Successful implementation of any of these approaches would depend on having appropriate resources (e.g., funding,
specially trained nurses, pharmacists and nonclinical support staff, time for training and/or collaborative meetings)
and awareness of available resources (e.g., primary care providers would need to know about free-educational
resources and/or collaborative opportunities).
Further evaluation, refinement and promulgation of these approaches is desirable, particularly in light of the
potential advent of a disease-modifying treatment for AD that might dramatically increase demand. But even in the
absence of a disease-modifying treatment, the aging population [82] and the ensuing increased burden of cognitive
decline mean that such novel care collaborations and models are dearly needed.
Future perspective
The advent of disease-modifying Alzheimer’s treatment will likely stress the capacity of healthcare systems to
identify and initiate treatment quickly enough for patients with mild cognitive impairment to slow the progression
to Alzheimer’s dementia. Innovative care approaches to develop collaborative multidisciplinary team matrices,
strengthen primary care capabilities and efficiently leverage specialist time would be pivotal to delivering timely
care. Going forward, we expect routine diagnosis and management of AD to shift to primary care settings, as we have
witnessed for other population-level chronic diseases, like depression, heart failure and diabetes. Our review shows
several models for deeper involvement of primary care with different approaches how roles and responsibilities
are divided between primary and specialty care. Which of these models will be adapted will be a function of
the existing care system. In pluralistic systems, like the USA, adaptation will follow local market conditions and
business objectives, whereas centrally planned systems, like France and the UK, will see a more unified approach. In
countries with devolved decision making, like Canada and Germany, regional stakeholders will negotiate changes.
Whatever the pathway to adaptation, decision makers will need solid real-world evidence to allocate resources
efficiently and fairly.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/sup
pl/10.2217/nmt-2020-0038
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Summary points
Introduction
• While the potential advent of a disease-modifying Alzheimer’s treatment offers great hope to patients and their
loved ones, research shows that health systems are ill-prepared to handle the complexity and volume of
identifying treatment-eligible patients.
• Scarcity of dementia specialists appears to be not only the most constraining factor but also the one that is the
hardest to address, as it difficult to increase the number of specialists in the short run.
Materials & methods
• This narrative synthesis based on 17 semi-structured interviews of practicing physicians in Canada and the USA
explores different possible approaches to memory care.
Results
• There are four care approaches with varying degrees and roles of primary and specialty care involvement that
may help alleviate specialist capacity constraint:
• Community primary care practices empowered with better tools and training;
• Primary care memory clinics;
• Specialty memory clinics;
• Specialty memory centers.
Discussion & conclusion
• These care approaches can be further adapted to best fit the local context.
• With proper training, tools and specialist support, primary care would be capable of assuming a greater role in
the evaluation of memory complaints and determination of treatment eligibility of Alzheimer’s disease
disease-modifying treatments.
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41. Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB. Comparing the electronic and standard versions of the Montreal
cognitive assessment in an outpatient memory disorders clinic: a validation study. J. Alzheimers Dis. 62(1), 93–97 (2018).
42. Wild K, Howieson D, Webbe F, Seelye A, Kaye J. Status of computerized cognitive testing in aging: a systematic review. Alzheimers
Dement. 4(6), 428–437 (2008).
43. Darby D, Brodtmann A, Woodward M, Budge M, Maruff P. Using cognitive decline in novel trial designs for primary prevention and
early disease-modifying therapy trials of Alzheimer’s disease. Int. Psychogeriatr. 23(9), 1376–1385 (2011).
44. Iliffe S, Wilcock J, Drennan V et al. Programme grants for applied research. In: Changing Practice in Dementia Care in the Community:
Developing and Testing Evidence-Based Interventions, from Timely Diagnosis to End of Life (EVIDEM). NIHR Journals Library,
Southampton, UK (2015).
45. Yale School of Medicine. Connecticut Older Adult Collaboration for Health (COACH). (2019).
https://medicine.yale.edu/intmed/geriatrics/agingresources/coach/
46. Arora S, Kalishman S, Dion D et al. Partnering urban academic medical centers and rural primary care clinicians to provide complex
chronic disease care. Health Aff. (Millwood) 30(6), 1176–1184 (2011).
47. Lewiecki EM, Rochelle R. Project ECHO: telehealth to expand capacity to deliver best practice medical care. Rheum. Dis. Clin. North
Am. 45(2), 303–314 (2019).
48. Carlin L, Zhao J, Dubin R, Taenzer P, Sidrak H, Furlan A. Project ECHO telementoring intervention for managing chronic pain in
primary care: insights from a qualitative study. Pain Med. 19(6), 1140–1146 (2018).
49. Khatri K, Haddad M, Anderson D. Project ECHO: replicating a novel model to enhance access to hepatitis C care in a community
health center. J. Health Care Poor Underserved 24(2), 850–858 (2013).
50. Bankhurst A, Romero-Olivas C, Larson HJ et al. Rheumatology care in under-resourced areas using the Extension for Community
Healthcare Outcomes Model. Arthritis Care Res (Hoboken) 72(6), 850–858 (2020).
51. Bouchonville MF, Paul MM, Billings J, Kirk JB, Arora S. Taking telemedicine to the next level in diabetes population management: a
review of the endo ECHO model. Curr. Diab. Rep. 16(10), 96 (2016).
52. Bennett KA, Ong T, Verrall AM, Vitiello MV, Marcum ZA, Phelan EA. Project ECHO-geriatrics: training future primary care providers
to meet the needs of older adults. J. Grad. Med. Educ. 10(3), 311–315 (2018).
C technology on healthcare
53. De Witt Jansen B, Brazil K, Passmore P et al. Evaluation of the impact of telementoring using ECHO
professionals’ knowledge and self-efficacy in assessing and managing pain for people with advanced dementia nearing the end of life.
BMC Health Serv. Res. 18(1), 228 (2018).

54. Alzheimer’s Association. The Alzheimer’s and dementia care ECHO program (2019).
www.alz.org/prof essionals/prof essional-providers/echo-alzheimers-dementia-care-program
55. Alzheimer’s Association. Alzheimer’s association launches pilot program to connect dementia care experts with assisted-living
communities (2019). www.alz.org/news/2018/alzheimer s association launches pilot program to#:∼:
text=Alzheimer’s%20Association%20Launches%20Pilot%20Program,Experts%20With%20Assisted%2DLiving%20Communities&t
ext=The%20six%2Dmonth%20program%20will,care%20in%20community%2Dbased%20settings
56. Wilcock J, Iliffe S, Griffin M et al. Tailored educational intervention for primary care to improve the management of dementia: the
EVIDEM-ED cluster randomized controlled trial. Trials 14, 397 (2013).
57. Downs M, Turner S, Bryans M et al. Effectiveness of educational interventions in improving detection and management of dementia in
primary care: cluster randomised controlled study. BMJ 332(7543), 692–696 (2006).
58. Mcbain RK, Sousa JL, Rose AJ et al. Impact of project ECHO models of medical tele-education: a systematic review. J. Gen. Intern. Med.
34(12), 2842–2857 (2019).
•

This systematic review finds evidence that suggests the effectiveness of project ECHO models at improving outcomes in hepatitis
C, chronic pain, dementia and Type 2 diabetes.

59. Lee L, Hillier LM, Heckman G et al. Primary care-based memory clinics: expanding capacity for dementia care. Can. J. Aging 33(3),
307–319 (2014).

future science group

www.futuremedicine.com

249

Special Report

Lam & Mattke

60. Lee L, Kasperski MJ, Weston WW. Building capacity for dementia care: training program to develop primary care memory clinics. Can.
Fam. Physician 57(7), e249–252 (2011).
61. Pimlott NJ, Siegel K, Persaud M et al. Management of dementia by family physicians in academic settings. Can. Fam. Physician 52(9),
1108–1109 (2006).
62. Lee L, Hillier LM, Stolee P et al. Enhancing dementia care: a primary care-based memory clinic. J. Am. Geriatr. Soc. 58(11), 2197–2204
(2010).
•

Describes the implementation of a primary-care led interdisciplinary memory clinic, which lead to higher diagnostic rates.

63. Lee L, Hillier LM, Molnar F, Borrie MJ. Primary care collaborative memory clinics: building capacity for optimized dementia care.
Healthc. Q 19(4), 55–62 (2017).
64. Lee L, Hillier LM, Mckinnon Wilson J et al. Effect of primary care-based memory clinics on referrals to and wait-time for specialized
geriatric services. J. Am. Geriatr. Soc. 66(3), 631–632 (2018).
65. CAHO. Memory Clinics expanded to underserviced areas in
Ontario (2017). http://caho-hospitals.com/memory-clinics-expanded-to-underserviced-areas-in-ontario/#:∼:text=Toronto%2C%20Ja
nuary%2023%2C%202017%20%E2%80%93,underserviced%20communities%20across%20the%20province
66. Greaves I, Greaves N, Walker E, Greening L, Benbow SM, Jolley D. Gnosall primary care memory clinic: eldercare facilitator role
description and development. Dementia (London) 14(4), 389–408 (2015).
67. Benbow SM, Jolley D, Greaves IC, Walker E. Closing the diagnosis gap and improving care: the primary care memory clinic. Prog.
Neurol. Psychiatry 17(6), 27–30 (2013).
68. Jedenius E, Wimo A, Strömqvist J, Andreasen N. A Swedish programme for dementia diagnostics in primary healthcare. Scand. J. Prim.
Health Care 26(4), 235–240 (2008).
69. Engedal K, Gausdal M, Gjøra L, Haugen PK. Assessment of dementia by a primary health care dementia team cooperating with the
family doctor - the Norwegian model. Dement. Geriatr. Cogn. Disord. 34(5–6), 263–270 (2012).
70. Jolley D, Benbow SM, Grizzell M. Memory clinics. Postgrad Med. J. 82(965), 199–206 (2006).
•

Provides an overview of memory clinics, summarizing its history, goals, organization and functions.

71. Johns Hopkins Medicine. Memory and Alzheimer’s Treatment Center (2019).
www.hopkinsmedicine.org/psychiatry/specialty areas/memory center/patient inf ormation.html
72. University of California, San Francisco. Memory and Aging Center Clinic (2019).
https://memory.ucsf.edu/memory-and-aging-center-clinic
73. Kaiser Permanente. Memory Clinic, San Jose (2019).
https://thrive.kaiserpermanente.org/care-near-you/northern-calif ornia/sanjose/departments/memory-clinic/
74. Kaiser Permanente. Memory Clinic, Napa Solano (2019).
https://thrive.kaiserpermanente.org/care-near-you/northern-calif ornia/napasolano/departments/memory-clinic/
75. Johannessen KA, Alexandersen N. Improving accessibility for outpatients in specialist clinics: reducing long waiting times and waiting
lists with a simple analytic approach. BMC Health Serv. Res. 18(1), 827 (2018).
76. Cummings J, Zhong K, Bernick C. The Cleveland Clinic Lou Ruvo Center for brain health: keeping memory alive. J. Alzheimers Dis.
38(1), 103–109 (2014).
77. Schreiber SS. Teleneurology for veterans in a major metropolitan area. Telemed. J. E Health 24(9), 698–701 (2018).
78. Keeping Memory Alive (2019). www.keepmemoryalive.org/
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